A Phase 1b, Open-label, Multicenter Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Formulations of a Single Subcutaneous Dose of Teprotumumab Followed by Multiple Intravenous Doses of TEPEZZA in Participants With Thyroid Eye Disease
Latest Information Update: 25 Jun 2024
At a glance
- Drugs Teprotumumab (Primary) ; Teprotumumab (Primary)
- Indications Graves ophthalmopathy
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Horizon Pharma USA
Most Recent Events
- 03 May 2024 New trial record